👤 Shude Xu

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
1613
Articles
1035
Name variants
Also published as: Ting-Xin Xu, Shuang Xu, Renyuan Xu, Cheng Xu, Xiao Xu, Jia-Chen Xu, Shengjie Xu, Yanyong Xu, Nong Xu, D-J Xu, Hongfa Xu, Shiyi Xu, Yunjian Xu, Maochang Xu, Lingyan Xu, Guoheng Xu, Zaibin Xu, Yuexuan Xu, Jinhe Xu, Yitong Xu, Yaping Xu, Miao Xu, Hongming Xu, Jiang Xu, Feng-Qin Xu, Zaihua Xu, Yaru Xu, Qiuyu Xu, Mingcong Xu, Yuanzhong Xu, Mai Xu, Biao Xu, Jingjun Xu, Shuwan Xu, Ya-Ru Xu, Zhilong Xu, Jun-Chao Xu, Shutao Xu, TianBo Xu, Jinyu Xu, Jie-Hua Xu, Peng Xu, Guo-Xing Xu, Yushan Xu, Yongsong Xu, Xin-Rong Xu, Bilin Xu, Xiang-Min Xu, Xiaolong Xu, Jinchao Xu, Han Xu, Xuting Xu, Yu Xu, Yingqianxi Xu, Yanyang Xu, Aili Xu, Weizhi Xu, Peidi Xu, Tongyang Xu, Tieshan Xu, Wen-Juan Xu, Jianping Xu, Bing Xu, Chengyun Xu, Xiaofeng Xu, Zhengang Xu, Guang-Hong Xu, Fangui Xu, Shan-Shan Xu, Hailiang Xu, Song-Song Xu, Quanzhong Xu, Mengqi Xu, Dawei Xu, Gezhi Xu, Linyan Xu, Yidan Xu, Tonghong Xu, Meishu Xu, Panpan Xu, Keli Xu, Xiufeng Xu, Hongwen Xu, Hanyuan Xu, Liang Xu, Zaoyi Xu, Fengqin Xu, Run-Xiang Xu, Xiaoyan Xu, Ruxiang Xu, Huiming Xu, Daqian Xu, Qin-Zhi Xu, Boming Xu, Jiancheng Xu, Zihao Xu, Jinghong Xu, Aimin Xu, Renfang Xu, Ran Xu, Di-Mei Xu, Xiang-liang Xu, Yana Xu, Richard H Xu, Yanchang Xu, Danyi Xu, Chengqi Xu, Lingli Xu, Xiaocheng Xu, Xiaoshuang Xu, H X Xu, Min Xu, Ya'nan Xu, Zhi Ping Xu, Zihe Xu, Hongle Xu, Xuan Xu, Jielin Xu, Yuping Xu, Yinli Xu, Limin Xu, Renshi Xu, Da Xu, C C Xu, Yongqing Xu, Heping Xu, Yiquan Xu, Weilan Xu, Jingjing Xu, Yangxian Xu, Yifan Xu, Congjian Xu, Binqiang Xu, Wentao Xu, Yuerong Xu, Jiaqi Xu, Shang-Fu Xu, Jiachi Xu, Yuejuan Xu, Zhi-Qing David Xu, Chao Xu, Yi-Xian Xu, Longfei Xu, Ziwei Xu, Mengyue Xu, Jingying Xu, Wenhui Xu, Zi-Xiang Xu, Caixia Xu, Chenjie Xu, Xiaoting Xu, Jiacheng Xu, Chunhui Xu, Chengxun Xu, Hengyi Xu, Songsong Xu, Lingyao Xu, Qingqiu Xu, Gangchun Xu, Yanjun Xu, Qiong Xu, Zifan Xu, Wenxuan Xu, Jiayunzhu Xu, Yifeng Xu, DongZhu Xu, Lingna Xu, Qianzhu Xu, Bocheng Xu, Qingjia Xu, Yanni Xu, Li-Yan Xu, Benhong Xu, Fang Xu, Xingsheng Xu, Geyang Xu, Anqi Xu, Zeao Xu, Mengsi Xu, Jun Xu, Qiuhong Xu, Ning'an Xu, Lian-Wei Xu, H F Xu, Hua Xu, Danping Xu, Xiaofang Xu, Shanshan Xu, Sheng-Qian Xu, Bingxin Xu, Ke Xu, Shiqing Xu, Cunshuan Xu, Guangwei Xu, Changwu Xu, Beibei Xu, Zhuangzhuang Xu, Chong-Feng Xu, Yunyi Xu, Yunxuan Xu, Zeya Xu, Jinshu Xu, Xinyu Xu, Laizhi Xu, Meiyu Xu, Bi-Yun Xu, Mingliang Xu, Weixia Xu, Bingfang Xu, Suling Xu, W W Xu, Lidan Xu, Chengkai Xu, Feng Xu, Yunhe Xu, Zesheng Xu, Li Xu, Song Xu, Yungen Xu, Yaobo Xu, Qinli Xu, Yi-Liang Xu, Tan Xu, Dong Xu, Ruiling Xu, Wanqi Xu, Ziyang Xu, Xiaohong Ruby Xu, Guangyu Xu, Xiao-Shan Xu, Wenxin Xu, Yongsheng Xu, Jingya Xu, Zhong-Hua Xu, Jiajie Xu, Dan Xu, Youjia Xu, Longsheng Xu, Mengjie Xu, Guo-Tong Xu, Ting Xu, Chunwei Xu, Tianmin Xu, Xianghong Xu, Nenggui Xu, Meixi Xu, Hongxia Xu, Rongying Xu, Guoliang Xu, Lisi Xu, Leisheng Xu, Xianli Xu, Yurui Xu, Honglin Xu, Yunfang Xu, Guo Xu, Shengyu Xu, Kelin Xu, Xiaoqin Xu, Zheng Xu, Junchang Xu, Jiaying Xu, Chunyu Xu, Beisi Xu, Zhen-Guo Xu, Haonan Xu, Tianyi Xu, Haiman Xu, Lili Xu, Yi Xu, Dongju Xu, Qihang Xu, Zhongwei Xu, Zihua Xu, Qikui Xu, Li-Jun Xu, Zhijie Xu, Hanchen Xu, Qi-Qi Xu, Yaqi Xu, Daohua Xu, Shaonian Xu, Xihui Xu, D Xu, Ziqi Xu, Tian-Ying Xu, Xiangbin Xu, Chen-Run Xu, Bin Xu, Jianjuan Xu, Zhanyu Xu, Lingjuan Xu, Wenjie Xu, Shuwen Xu, Cian Xu, Yu-Ming Xu, Qiulin Xu, Zeyu Xu, Jia Xu, Zengliang Xu, Yujie Xu, Yuting Xu, Jing-Yi Xu, Jiajia Xu, Xiqi Xu, Leiyu Xu, Shi-Na Xu, Ruonan Xu, Wenhuan Xu, Bai-Hui Xu, Jishu Xu, Xiangyu Xu, Lu-Lu Xu, Shiyun Xu, Huaxiang Xu, Lei Xu, Yuli Xu, Chan Xu, Tengfei Xu, Yong Xu, Xuejun Xu, Hang Xu, Junjie Xu, Jinjie Xu, Haoda Xu, Rui-Ming Xu, Yunxi Xu, Jinghua Xu, Ye Xu, Jiyi Xu, Mei-Jun Xu, Jianyong Xu, Yingzheng Xu, Kaiyue Xu, Yeqiu Xu, Songli Xu, Cheng-Jian Xu, Chenqi Xu, Qiaoshi Xu, Rongrong Xu, YanFeng Xu, Jin Xu, Huimian Xu, Zaikun Xu, Aixiao Xu, Yanfei Xu, Chunlin Xu, Huiqiong Xu, Dapeng Xu, Fengxia Xu, Yongmei Xu, Yubin Xu, Xiaojing Xu, Xiaoli Xu, Pu Xu, Wenming Xu, Wenjing Xu, Wenjuan Xu, Haijin Xu, Yawei Xu, Chuanrui Xu, Wenping Xu, Tongtong Xu, Yinfeng Xu, Zhigang Xu, Zi-Hua Xu, Jiean Xu, Ming Xu, Keshu Xu, Weili Xu, Guofeng Xu, Ai-Guo Xu, Xingyu Xu, Shujing Xu, Weiqun Xu, Wen-Hao Xu, Hong-wei Xu, Jianfeng Xu, Y Xu, Steven Jing-Liang Xu, Fangfang Xu, Xiao-Dan Xu, Keyun Xu, Yetao Xu, Qianhui Xu, Chaoqun Xu, Yuzhi Xu, Fenghuang Xu, Tengxiao Xu, Zelin Xu, Xueni Xu, Jing-Ying Xu, Yichi Xu, Ruifeng Xu, Kewei Xu, Fang-Fang Xu, Jiapeng Xu, Sifan Xu, Pengli Xu, Jiaqin Xu, Xiaotao Xu, Chunming Xu, X Xu, Xinyin Xu, Gang Xu, Wei Xu, Yuzhen Xu, Wancheng Xu, Qiming Xu, Hailey Xu, Yuanyuan Xu, Xiaoming Xu, Yimeng Xu, Shihao Xu, Zhipeng Xu, Minxuan Xu, Haowen Xu, Dilin Xu, Rui Xu, Jingzhou Xu, Qiongying Xu, Zhengshui Xu, Jinyi Xu, Q P Xu, Yongjian Xu, Qiushi Xu, Junfei Xu, Hui Ming Xu, Mengjun Xu, Xiaolei Xu, Yanzhe Xu, Qin Xu, Zichuan Xu, Xinyun Xu, Xiaoge Xu, Tianyu Xu, Yigang Xu, Lanjin Xu, Hongyan Xu, Guowang Xu, Jingjie Xu, Yangyang Xu, Yi-Huan Xu, Guanhua Xu, Hongrong Xu, Fen Xu, Pin-Xian Xu, Jian Xu, Tiantian Xu, Zhonghui Xu, Changfu Xu, Dong-Hui Xu, Jialu Xu, Yi-Ni Xu, Yuzhong Xu, Hongli Xu, Mingyuan Xu, Minghao Xu, Qinghua Xu, C F Xu, Yiting Xu, Qian Xu, Jiahong Xu, Haixiang Xu, Xizheng Xu, Kun Xu, Yunfei Xu, Xiaoyang Xu, Xiaojun Xu, Xinyuan Xu, Guogang Xu, Chen Xu, Jinguo Xu, Guiyun Xu, Lingyi Xu, Wenbin Xu, Chunjie Xu, Manman Xu, Cheng-Bin Xu, Dongke Xu, Jia-Mei Xu, Bing-E Xu, Lijiao Xu, You-Song Xu, Mengmeng Xu, Yu-Xin Xu, Jianwei Xu, Kuanfeng Xu, Chun Xu, Shiliyang Xu, Waner Xu, Zhiyao Xu, Gu-Feng Xu, Wenyuan Xu, J T Xu, Haifeng Xu, Chaohua Xu, Ling Xu, Lisha Xu, Xiayun Xu, Qian-Fei Xu, Huaisha Xu, Jinying Xu, Tengyun Xu, Chaoguang Xu, Fuyi Xu, Shihui Xu, Yingna Xu, Aishi Xu, Yanyan Xu, Qiuhui Xu, Bilian Xu, Jinsheng Xu, Qinwen Xu, Tianfeng Xu, Liyi Xu, Lihui Xu, Guanyi Xu, Ru-xiang Xu, Wenyan Xu, Zongzhen Xu, Nan Xu, Rui-Xia Xu, Jinxian Xu, Zhiting Xu, Jiaming Xu, Shan-Rong Xu, Yi-Tong Xu, Xiaojuan Xu, Guifa Xu, Xia-Jing Xu, Libin Xu, Dequan Xu, Guoxu Xu, Lubin Xu, Hong Xu, Cai Xu, Mengying Xu, Tian-Le Xu, J Xu, Weidong Xu, Chengbi Xu, Yibin Xu, Cong-jian Xu, Qianlan Xu, Tingting Xu, Caiqiu Xu, Hong-Yan Xu, Hanqian Xu, Xiao Le Xu, Bei Xu, Guanlan Xu, Jianxin Xu, Ming-Zhu Xu, Long Xu, Xiaopeng Xu, Yinjie Xu, Shufen Xu, Zhihua Xu, Di Xu, Ming-Jiang Xu, Qingwen Xu, Jiake Xu, Tingxuan Xu, Ping Xu, Peng-Ju Xu, Li-Zhi Xu, Shang-Rong Xu, Baoping Xu, Huan Xu, Wenwu Xu, Zhenyu Xu, Chong Xu, Sihua Xu, Anlong Xu, Lu Xu, Chen-Yang Xu, Xiaoyu Xu, Zhe Xu, Qiuyue Xu, Guangquan Xu, Peiyu Xu, Huihui Xu, Ding Xu, Yuchen Xu, Jianguo Xu, Lingyang Xu, Xuegong Xu, Jia-Yue Xu, Liping Xu, Yuling Xu, Yiyi Xu, Jianqiu Xu, Lichi Xu, Xiaojiang Xu, Zhaofa Xu, Xiao-Hui Xu, Mao Xu, Yuyang Xu, Qingchan Xu, Yanli Xu, Julie Xu, Minglan Xu, G Xu, Yao Xu, Yali Xu, Miaomiao Xu, Yanqi Xu, Tian Xu, Xiaojin Xu, Xiaowen Xu, Lingxiang Xu, Qing-Yang Xu, Jianguang Xu, Zhanchi Xu, Shiwen Xu, Haikun Xu, Hongbei Xu, Yixin Xu, Zhan Xu, Fangmin Xu, Xingshun Xu, Wenzhuo Xu, Fu Xu, Haimin Xu, Shengtao Xu, Jiahui Xu, Zhiwei Xu, Peiwei Xu, Daichao Xu, Wen-Hui Xu, Xingyan Xu, H Eric Xu, Zhi-Feng Xu, Mingming Xu, Hongtao Xu, Keman Xu, Daiqi Xu, Yinying Xu, Yuexin Xu, Yuanwei Xu, Xuanqi Xu, Jinfeng Xu, L Xu, Chunyan Xu, Hanting Xu, Chaoyu Xu, Tiancheng Xu, Shendong Xu, Guangsen Xu, Chentong Xu, Yaozeng Xu, Banglao Xu, Tao Xu, Danyan Xu, Ren-He Xu, Haiyan Xu, Jian-Guang Xu, Yu-Fen Xu, Youzhi Xu, Hui Xu, Enwei Xu, F F Xu, Ningda Xu, Zejun Xu, N Y Xu, Li-Wei Xu, Xiaoya Xu, Ren Xu, Ze-Jun Xu, Yanan Xu, Jiapei Xu, Peigang Xu, Tianxiang Xu, Haiqi Xu, Qing-Wen Xu, Junnv Xu, Tian-Rui Xu, Wanfu Xu, Wang-Hong Xu, Maotian Xu, Suoyu Xu, Mingli Xu, Qingqing Xu, Liwen Xu, Zhenming Xu, Jingyi Xu, Yihua Xu, Dong-Juan Xu, Mu Xu, Meifeng Xu, Li-Ling Xu, Dongmei Xu, Jianliang Xu, Pengfei Xu, Xinjie Xu, Changlin Xu, Shuai Xu, Fang-Yuan Xu, Yingli Xu, Ying Xu, Guo-Liang Xu, Zhiqiang Xu, Xirui Xu, Haiying Xu, Wen Xu, Wenwen Xu, Xiaoyin Xu, Mengping Xu, Jing-Yu Xu, Chunlan Xu, Danfeng Xu, Yuan Xu, Wenchun Xu, Zekuan Xu, Nuo Xu, Shuxiang Xu, Min Jie Xu, Penghui Xu, Bingqi Xu, Zixuan Xu, Hongen Xu, Zongli Xu, Tianli Xu, Bo Xu, Zhaojun Xu, Qingyuan Xu, Min-Xuan Xu, Shuhua Xu, Xu Xu, Runhao Xu, M Xu, Zhaoyao Xu, Xiongfei Xu, Yingju Xu, Yayun Xu, Kaixiang Xu, Guang-Qing Xu, Lingling Xu, Jiyu Xu, Anton Xu, Jason Xu, Donghang Xu, Xiaowu Xu, Fengzhe Xu, Xia Xu, Xiangshan Xu, Wan-Ting Xu, Fengyan Xu, Qingheng Xu, Changlu Xu, Huaiyuan Xu, Jinsong Xu, Dongchen Xu, Rang Xu, Peng-Yuan Xu, Jinyuan Xu, Weihong Xu, Wanxue Xu, Xinyi Xu, Jie Xu, Junfeng Xu, Danning Xu, Haiming Xu, Sutong Xu, Shan Xu, Meng Xu, Yueyue Xu, Jixuan Xu, Hongjian Xu, Zhidong Xu, Jinjin Xu, Xiaobo Xu, Hongmei Xu, Shu-Xian Xu, Chuang Xu, Shuaili Xu, Yun Xu, Zhixian Xu, Yue Xu, George X Xu, Man Xu, Jiaai Xu, Zeqing Xu, Baijie Xu, Zheng-Fan Xu, Bojie Xu, Mengru Xu, H Y Xu, Yinhe Xu, Linna Xu, Liqun Xu, Zhi-Zhen Xu, Xiaohui Xu, Yinxia Xu, Xingmeng Xu, Pan Xu, Pengjie Xu, Kexin Xu, Kai Xu, Xiaolin Xu, Cun Xu, Yuxiang Xu, Tong Xu, Jingyu Xu, Li-Li Xu, Yancheng Xu, Chunxiao Xu, Yan Xu, Huajun Xu, Hongjiang Xu, Shuiyang Xu, Kaihao Xu, Suo-Wen Xu, Heng Xu, Zebang Xu, Hongbo Xu, Chenhao Xu, Fanghua Xu, Yaowen Xu, Jing Xu, Qianqian Xu, Andrew Z Xu, Flora Mengyang Xu, Yuanzhi Xu, Leilei Xu, Leyuan Xu, M-Y Xu, Hongzhi Xu, Zongren Xu, Xinyue Xu, Qingxia Xu, Xiao-Hua Xu, Cineng Xu, Nannan Xu, Guoshuai Xu, Mingzhu Xu, X S Xu, Guang Xu, Song-Hui Xu, Zhiyang Xu, Wang-Dong Xu, De-Xiang Xu, Yi Ran Xu, Shengen Xu, Jianzhong Xu, F Xu, Dexiang Xu, Rui-Hua Xu, Tongxin Xu, Wanting Xu, Bingqian Xu, Yang Xu, Jiaqian Xu, Yu-Ping Xu, Zhanqiong Xu, Haixia Xu, Hao Xu, HuiTing Xu, Hanfei Xu, Shu-Zhen Xu, Zhong Xu, Xun Xu, Xiaolu Xu, S Xu, Ning Xu, Guangyan Xu, Chengye Xu, Xizhan Xu, Ya-Peng Xu, Jianming Xu, Wenhao Xu, Minghong Xu, Mingqian Xu, Yaqin Xu, Chang-Qing Xu, Weiyong Xu, Huixuan Xu, Jialin Xu, Z Xu, Fei Xu, Pao Xu, Youping Xu, Keke Xu, Jia-Li Xu, Shunjiang Xu, Feilai Xu, Yucheng Xu, Qi Xu, Jinhua Xu, Chunli Xu, Zhiliang Xu, Jinxin Xu, Lianjun Xu, Lifen Xu, Bingqing Xu, Weihai Xu, Wenqi Xu, Zheng-Hong Xu, Lin Xu, Zuojun Xu, Yanquan Xu, Yanwu Xu, Mingjie Xu, Hui-Lian Xu, Cong Xu, Dongjun Xu, Maodou Xu, Rong Xu, Haoyang Xu, Shanhai Xu, Haoyu Xu, Yinglin Xu, Wenqing Xu, Xiaoke Xu, Jiali Xu, Changliu Xu, Feng-Xia Xu, Carrie Xu, Yuheng Xu, Shimeng Xu, Wanwan Xu, Weiming Xu, Gui-Ping Xu, Zhenzhou Xu, Yangbin Xu, Aohong Xu, Wenlong Xu, Jia-Xin Xu, Luyi Xu, Manyi Xu, Xinxuan Xu, De Xu, Changde Xu, Gaosi Xu, Baofeng Xu, Chang Xu, Wanhai Xu, Qing Xu, Zuyuan Xu, Pingwen Xu, Feng-Yuan Xu, Aoling Xu, Erping Xu, Shaoqi Xu, Zhicheng Xu, Lun-Shan Xu, Shiyao Sherrie Xu, Jianing Xu, Boqing Xu, Janfeng Xu, Yin Xu, Weijie Xu, Yu-Peng Xu, Ya-Nan Xu, Gaoyuan Xu, Zhi Xu, Xiaomeng Xu, Iris M J Xu, Mengyi Xu, Meifang Xu, Houxi Xu, Yuanfeng Xu, Shuqia Xu, Da-Peng Xu, Hong-tao Xu, Yaling Xu, Mei Xu, Xiaojiao Xu, Zhiru Xu, Dandan Xu, Weide Xu, W Xu, Shun Xu, Jianhua Xu, Tongda Xu, Cynthia M Xu, Yechun Xu, Lijun Xu, Xiao-Lin Xu, Ziye Xu, Xiaohan Xu, Guozheng Xu, Rongbin Xu, Nathan Xu, Wangdong Xu, Kailian Xu, Yongfeng Xu, Zhunan Xu, Jiawei Xu, Ruohong Xu, Yuhan Xu, Shanqi Xu, Shoujia Xu, T Xu, Weifeng Xu, Qiuyun Xu, Hu Xu, Yanming Xu, Hongwei Xu, Ziyu Xu, Kaishou Xu, Jian Hua Xu, Xin Xu, Liu Xu, Zetan Xu, Leiting Xu, Yong-Nan Xu, Houguo Xu, Zhizhen Xu, Ya-lin Xu, Xiang Xu, Suowen Xu, Xuejin Xu, Yiming Xu, Genxing Xu, Yun-Teng Xu, Yanling Xu, Yuanhong Xu, Lijuan Xu, Xingzhi Xu, Guanghao Xu, Qiu-Han Xu, Siqun Xu, Wen-Xiong Xu, Qianghua Xu, Shuangbing Xu, Wenjun Xu, Jiangang Xu, Yangliu Xu, Jinjian Xu, W M Xu, Shanqiang Xu, Zefeng Xu
articles
Jiawei Li, Ximei Li, Jiamin Tian +5 more · 2025 · Frontiers in veterinary science · Frontiers · added 2026-04-24
Lower intramuscular fat (IMF) and excessive abdominal fat reduce carcass quality in broilers. The study aimed to investigate the effects of dietary VD
📄 PDF DOI: 10.3389/fvets.2025.1542637
APOB
Juan Zhou, Shanshan Wang, Qiang Wang +11 more · 2025 · Food & function · Royal Society of Chemistry · added 2026-04-24
Central obesity poses a significant health threat. Lutein-rich fruits and vegetables may help manage obesity. Limited evidence suggests that lutein exerts health effects by inhibiting advanced glycati Show more
Central obesity poses a significant health threat. Lutein-rich fruits and vegetables may help manage obesity. Limited evidence suggests that lutein exerts health effects by inhibiting advanced glycation end products (AGEs), but data on its effects in centrally obese individuals are sparse. Thus, we aimed to investigate the effects of lutein supplementation in subjects with central obesity. A double-blind, randomized controlled trial was conducted involving patients with central obesity. Anthropometric indices, dietary intake, metabolic parameters, carotenoid and AGEs levels were compared between those receiving a 32-week intervention of 10 mg d Show less
no PDF DOI: 10.1039/d4fo05578k
APOB
Ling-Ling Wang, Zi-Xiang Xu, Bo-Qian Sun +3 more · 2025 · Angiology · SAGE Publications · added 2026-04-24
Lipid ratio is a balance between atherogenesis and antiatherogenesis. it is an important predictive marker of carotid plaque. The lipid ratios, which include non-high-density lipoprotein cholesterol ( Show more
Lipid ratio is a balance between atherogenesis and antiatherogenesis. it is an important predictive marker of carotid plaque. The lipid ratios, which include non-high-density lipoprotein cholesterol (non-HDL-C)/high-density lipoprotein cholesterol (HDL-C), remnant cholesterol (RC)/HDL-C, apolipoprotein B (ApoB)/apolipoprotein A1 (ApoA1), low-density lipoprotein cholesterol (LDL-C)/HDL-C, ApoB/HDL-C, total cholesterol (TC)/HDL-C, triglycerides (TG)/HDL-C, were included and analyzed. Sex differences in the relationship between lipid ratios and carotid plaque were discussed. The risk of carotid plaque was found to be significantly associated with the Non-HDL-C /HDL-C, RC/HDL-C, ApoB/ApoA1, LDL-C /HDL-C, ApoB/HDL-C, TC/HDL-C in females but not in males. The ApoB/HDL risk presented the highest relationship with carotid plaque in females only. The predictive value of the aforementioned lipid ratios for carotid plaque was observed in females only. Show less
no PDF DOI: 10.1177/00033197251316624
APOB
Peiwei Xu, Min Nian, Jie Xiang +8 more · 2025 · Environmental science & technology · ACS Publications · added 2026-04-24
Per- and polyfluoroalkyl substances (PFAS) pose potential health risks to lipid metabolism, but the effects of emerging PFAS alternatives, particularly in children, remain unclear. This cross-sectiona Show more
Per- and polyfluoroalkyl substances (PFAS) pose potential health risks to lipid metabolism, but the effects of emerging PFAS alternatives, particularly in children, remain unclear. This cross-sectional study investigated the association between emerging PFAS exposure and lipid levels in 294 Chinese children aged 7-10 years, analyzing blood samples for 14 PFAS and lipid profiles, including triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), apolipoprotein A1 (ApoA1), and apolipoprotein B (ApoB). Exposure to 6:2 Cl-PFESA, PFO4DA, and PFO5DoDA was associated with higher TC, TG, and LDL levels, with PFO4DA increasing the TC by 1.7% and PFO5DoDA increasing the TG by 10.7%. Weighted quantile sum (WQS) regression showed mixed PFAS exposure positively associated with TG (0.08, 95% CI: 0.007, 0.153). PFO4DA had the highest weight for TC (0.468), TG (0.327), LDL (0.57), ApoA1 (0.243), and ApoB (0.466), while PFMOAA had the highest weight for HDL (0.332). Bayesian Kernel Machine Regression (BKMR) analysis confirmed positive associations between the PFAS mixture and TC, TG, LDL, and ApoA1. Mediation analysis revealed that mtDNAcn significantly mediated PFAS exposure's effect on TG levels, explaining 27.2-74.2% of the total effect. These findings highlight the need for regulatory action to address the emerging PFAS risks. Show less
no PDF DOI: 10.1021/acs.est.4c13095
APOB
Ze-Yuan Yin, Shi-Min He, Xin-Yuan Zhang +16 more · 2025 · Acta pharmacologica Sinica · Nature · added 2026-04-24
Ovarian cancer presents a significant treatment challenge due to its insidious nature and high malignancy. As autophagy is a vital cellular process for maintaining homeostasis, targeting the autophagi Show more
Ovarian cancer presents a significant treatment challenge due to its insidious nature and high malignancy. As autophagy is a vital cellular process for maintaining homeostasis, targeting the autophagic pathway has emerged as an avenue for cancer therapy. In the present study, we identify apolipoprotein B100 (ApoB100), a key modulator of lipid metabolism, as a potential prognostic biomarker of ovarian cancer. ApoB100 functioned as a tumor suppressor in ovarian cancer, and the knockdown of ApoB100 promoted ovarian cancer progression in vivo. Moreover, ApoB100 blocked autophagic flux, which was dependent on interfering with the lipid accumulation/endoplasmic reticulum (ER) stress axis. The effects of LFG-500, a novel synthetic flavonoid, on ApoB100 induction were confirmed using proteomics and lipidomics analyses. Herein, LFG-500 induced lipid accumulation and ER stress and subsequently blocked autophagy by upregulating ApoB100. Moreover, data from in vivo experiments further demonstrated that ApoB100, as well as the induction of the lipid/ER stress axis and subsequent blockade of autophagy, were responsible for the anti-tumor effects of LFG-500 on ovarian cancer. Hence, our findings support that ApoB100 is a feasible target of ovarian cancer associated with lipid-regulated autophagy and provide evidence for using LFG-500 for ovarian cancer treatment. Show less
no PDF DOI: 10.1038/s41401-024-01470-x
APOB
Ping Huang, Yong Zhao, Haiyan Wei +8 more · 2025 · International journal of chronic obstructive pulmonary disease · added 2026-04-24
In preliminary research and literature review, we identified a potential link between chronic obstructive pulmonary disease (COPD) and lipid metabolism. Therefore, this study employed Mendelian random Show more
In preliminary research and literature review, we identified a potential link between chronic obstructive pulmonary disease (COPD) and lipid metabolism. Therefore, this study employed Mendelian randomization (MR) analysis to investigate the potential causal connection between blood lipids and COPD. A genome-wide association study (GWAS) on COPD was conducted, encompassing a total of 112,583 European participants from the MRC-IEU. Additionally, extensive UK Biobank data pertaining to blood lipid profiles within European cohorts included measurements for low-density lipoprotein cholesterol (LDL-C) with 440,546 individuals, high-density lipoprotein cholesterol (HDL-C) with 403,943 individuals, triglycerides (TG) with 441,016 individuals, total cholesterol (TC) with 187,365 individuals, apolipoprotein A-I (apoA-I) with 393,193 individuals, and apolipoprotein B (apoB) with 439,214 individuals. Then, MR analyses were performed for lipids and COPD, respectively. The primary analytical technique employed was the inverse-variance weighted (IVW) approach, which included a 95% confidence interval (CI) to calculate the odds ratio (OR). Additionally, a sensitivity analysis was conducted to assess the dependability of the MR analysis outcomes. MR analysis was primarily based on IVW, unveiled a causal link between COPD and LDL-C (OR=0.994, 95% CI (0.989, 0.999), P=0.019), TG (OR=1.005, 95% CI (1.002, 1.009), P=0.006), and apoA-I (OR=0.995, 95% CI (0.992, 0.999), P=0.008), in addition, no causal link was found with HDL-C, TC, apoB. Sensitivity analysis demonstrated the robustness of these causal relationships. However, through multivariate MR(MVMR) and multiple testing correction, LDL-C and TG had no causal effect on the outcome. ApoA-I remained a protective factor for the risk of COPD (OR=0.994, 95% CI (0.990-0.999), P=0.008). Through MR analysis, this study offers evidence of a causal link between apoA-I with COPD. This further substantiates the potential role of lipid metabolism in COPD, and has significant clinical implications for the prevention and management of COPD. Show less
📄 PDF DOI: 10.2147/COPD.S476833
APOB
Mengke Yan, Xin Cong, Hui Wang +7 more · 2025 · Poultry science · Elsevier · added 2026-04-24
Aging-related lipid metabolic disorder is related to oxidative stress. Selenium (Se)-enriched Cardamine violifolia (SEC) is known for its excellent antioxidant function. The objective of this study wa Show more
Aging-related lipid metabolic disorder is related to oxidative stress. Selenium (Se)-enriched Cardamine violifolia (SEC) is known for its excellent antioxidant function. The objective of this study was to evaluate the effects of SEC on antioxidant capacity and lipid metabolism in the liver of aged laying hens. A total of 450 sixty-five-wk-old Roman laying hens were randomly divided into 5 treatments: a basal diet (without Se supplementation, CON) and basal diets supplemented with 0.3 mg/kg Se from sodium selenite (SS), 0.3 mg/kg Se from Se-enriched yeast (SEY), 0.3 mg/kg Se from SEC (SEC), or 0.3 mg/kg Se from SEC and 0.3 mg/kg Se from SEY (SEC + SEY). The experiment lasted for 8 wk. The results showed that dietary SEC + SEY supplementation decreased (P < 0.05) triglyceride (in the plasma and liver) and total cholesterol levels (in the plasma), and increased (P < 0.05) HDL-C concentration in plasma compared to CON diet. Compared with CON diet, SEC and/or SEY supplementation decreased (P < 0.05) the mRNA expression of hepatic ACC, FAS and HMGCR, and increased (P < 0.05) PPARα, VTG-II, Apo-VLDL II and ApoB expression. Dietary SEC + SEY and SEY supplementation increased (P < 0.05) Se content in egg yolk and breast muscle compared to CON diet. Dietary SEC, SEY or SEC + SEY supplementation increased (P < 0.05) the activity of antioxidant enzymes (GSH-PX, T-AOC and T-SOD) in the plasma and liver and decreased (P < 0.05) MDA content in the plasma compared to CON diet. Dietary Se supplementation promoted (P < 0.05) mRNA expression of Nrf2 in the liver. In contrast, dietary SEY and SEC supplementation resulted in a decrease (P < 0.05) of hepatic Keap1 mRNA expression compared to CON diet. Dietary SEC + SEY and/or SEC supplementation increased (P < 0.05) mRNA expression of Selenof, GPX1 and GPX4 in the liver compared with CON diet. In conclusion, dietary SEC (0.3 mg/kg Se) or SEC (0.3 mg/kg Se) + SEY (0.3 mg/kg Se) improved the antioxidant capacity and the lipid metabolism in the liver of aged laying hens, which might be associated with regulating Nrf2/Keap1 signaling pathway. Show less
📄 PDF DOI: 10.1016/j.psj.2024.104620
APOB
Yuhui Lai, Shaozhao Zhang, Yue Guo +11 more · 2025 · American heart journal · Elsevier · added 2026-04-24
Elevated lipoprotein(a) (Lp[a]) and apolipoprotein B (apoB) are individually associated with the risk of atherosclerotic cardiovascular disease (ASCVD). Moreover, previous basic research has implicate Show more
Elevated lipoprotein(a) (Lp[a]) and apolipoprotein B (apoB) are individually associated with the risk of atherosclerotic cardiovascular disease (ASCVD). Moreover, previous basic research has implicated the potential interaction between apoB and Lp(a) in the atherogenic process. We aimed to determine whether apoB levels significantly modulate ASCVD risk associated with Lp(a) in a large community-based population without baseline cardiovascular disease. Plasma Lp(a) and apoB were measured in the Atherosclerosis Risk in Communities (ARIC) study. Elevated Lp(a) was defined as the highest race-specific quintile, and elevated apoB was defined as ≥89 mg/dl (median value). The modifying effect of apoB on the Lp(a)-related risk of ASCVD and coronary heart disease (CHD) was determined using Cox regression models adjusted for cardiovascular risk factors. Among 12,988 ARIC participants, 3,888 ASCVD events and 1754 CHD events were observed. Elevated apoB (≥89 mg/dl) and elevated Lp(a) (race-specific quintile 5) were independently associated with ASCVD (hazard ratio [HR]: 1.19; 95% CI: 1.08-1.30; P <0.001; HR: 1.27; 95% CI: 1.16-1.40; P < .001, respectively). Lp(a)-by-apoB interaction was noted [Lp(a) (quintile 1-4 or quintile 5) * apoB (<89 or ≥89 mg/dl) = 0.002]. Compared to the concordantly low Lp(a) group, the individuals with high Lp(a) had a greater ASCVD risk only when apoB was elevated (HR: 1.48; 95% CI: 1.34-1.63; P < .001). In the context of primary prevention, ASCVD risk associated with Lp(a) was observed only when apoB was elevated. The measurement of apoB can further refine and contextualize the ASCVD risk associated with Lp(a). Show less
no PDF DOI: 10.1016/j.ahj.2024.11.014
APOB
Yan Hu, Chao Quan, Yuanyuan Zhou +6 more · 2025 · PloS one · PLOS · added 2026-04-24
The differential diagnosis between Tuberculosis (TB) and Non-tuberculous Mycobacteria (NTM) has historically been constrained by the inadequate sensitivity and specificity of current diagnostic method Show more
The differential diagnosis between Tuberculosis (TB) and Non-tuberculous Mycobacteria (NTM) has historically been constrained by the inadequate sensitivity and specificity of current diagnostic methods. Furthermore, distinguishing between Active Tuberculosis (ATB) and Latent Tuberculosis Infection (LTBI) poses significant challenges. This study aims to develop a molecular differentiation system for ATB, LTBI, and NTM by integrating plasma proteomics with multi-dimensional analytical techniques, while also exploring key biomarkers associated with disease progression and treatment response. Using label-free quantitative technology, we conducted a plasma proteomics analysis across five groups: ATB, LTBI, NTM, Cured Patients (CPs), and Healthy Donors (HD). Differentially Expressed Proteins (DEPs) were identified through screening (FC > 1.5 or <0.67, P < 0.05), followed by Gene Ontology/KEGG pathway enrichment, STRING interaction network, and Mfuzz dynamic clustering analysis to systematically elucidate molecular characteristics. Experimental data were validated through a multidimensional quality control system (Pearson correlation coefficient, peptide distribution, molecular weight distribution, etc.). Enzyme-linked immunosorbent assay (ELISA) was employed to detect the plasma expression levels of target proteins across the groups and to facilitate comparisons. This study identified 1,338 non-redundant proteins across five cohorts. Comparative analysis revealed 142 DEPs across the three comparative groups (ATB, LTBI, and NTM), which were primarily localized in the extracellular domain. Key findings include: 27 DEPs in the ATB-LTBI group, primarily enriched in inflammatory responses (such as A2M, IL-1R2) and epithelial barrier functions (TGM3, KRT3); 69 DEPs in the ATB-NTM group, characterized by significant changes in immunoglobulin light chains (IGLV2-11) and innate immune effector molecules (S100A8); 46 DEPs in the NTM-LTBI group, closely related to lipid metabolism (APOC3) and extracellular matrix remodeling (FN1). KEGG pathway analysis revealed that DEPs in the ATB-LTBI group were enriched in nitrogen metabolism pathways, those in the ATB-NTM group were associated with thyroid hormone synthesis, and the NTM-LTBI group was involved in phagosome function. Dynamic clustering results showed six treatment response modules: Cluster 1/2 (riboflavin metabolism, complement coagulation pathway) were activated post-treatment, Cluster 3/4 (proteasome, cardiac signaling pathway) exhibited partial reversal in expression, and Cluster 5/6 (platelet activation, cytoskeleton) showed delayed regression. Research confirmed 10 differential proteins between the ATB-CPs and ATB-HD groups, including S100A8, LTA4H, and DEFA1B, which constitute a molecular fingerprint specific to ATB. ELISA validation confirmed significantly elevated S100A8 and GPX3 in ATB group, while NTM group showed higher FGB and lower ATRN levels. This study systematically reveals the plasma proteomic characteristics under infection statuses caused by different mycobacteria. A discrimination framework for ATB/LTBI/NTM was constructed based on disease-specific differential proteins, overcoming the limitations of traditional diagnostic techniques in distinguishing infection states. Through dynamic analysis of six temporal therapeutic modules, the reprogramming patterns of the host protein network during tuberculosis treatment were elucidated. This research lays a multidimensional molecular foundation for the precise typing, personalized treatment, and prognostic evaluation of mycobacterial infections. Show less
📄 PDF DOI: 10.1371/journal.pone.0339558
APOC3
Xingjing Liu, Huimei Yu, Tongtong Hu +7 more · 2025 · Diabetes, obesity & metabolism · Blackwell Publishing · added 2026-04-24
Abnormal lipid accumulation is an important cause of metabolic dysfunction-associated fatty liver disease (MAFLD) progression and can induce several stress responses within cells. This study is the fi Show more
Abnormal lipid accumulation is an important cause of metabolic dysfunction-associated fatty liver disease (MAFLD) progression and can induce several stress responses within cells. This study is the first to explore the role and molecular mechanism of stress granules (SGs) in MAFLD. A gene knock-down model of G3BP1, a core SG molecule in mice and HepG2 cells, was constructed to explore the role of SGs in MAFLD induced in vivo by a high-fat diet or in vitro by palmitic acid (PA). Methods included metabolic phenotyping; western blotting; qPCR; and immunofluorescence, haematoxylin/eosin and masson staining. The downstream molecules of G3BP1 and its specific molecular mechanism were screened using RNA sequencing (RNA-seq). G3BP1 and TIA1 expression were upregulated in high-fat diet-fed mouse liver tissues and PA-induced HepG2 cells, and the two molecules showed significantly increased colocalisation. G3BP1 knock-down slightly increased TIA1 expression in the livers of obese mice but not in lean mice. G3BP1 deficiency aggravated liver lipid deposition and insulin resistance in obese mice, and this phenotype was confirmed in vitro in PA-induced hepatocytes. RNA-seq demonstrated that G3BP1 slowed down MAFLD progression by inhibiting APOC3, possibly through a mechanistic suppression of APOC3 entry into the nucleus. This study reveals for the first time a protective role for SGs in MAFLD. Specifically, knocking down the core G3BP1 molecule in SGs aggravated the progression of fatty acid-induced MAFLD through a mechanism that may involve the nuclear entry of APOC3. These findings provide a new therapeutic direction for MAFLD. Show less
no PDF DOI: 10.1111/dom.16302
APOC3
Danyu Chen, Keliang Xie, Chang Gao +6 more · 2025 · The Journal of nutritional biochemistry · Elsevier · added 2026-04-24
Prior research has highlighted the significant roles of circulating retinol, retinol-binding protein 4 (RBP4), and apolipoprotein C (ApoC) in metabolic health. This study investigates the joint associ Show more
Prior research has highlighted the significant roles of circulating retinol, retinol-binding protein 4 (RBP4), and apolipoprotein C (ApoC) in metabolic health. This study investigates the joint association of retinol and RBP4 with metabolic syndrome (MetS) and examines the potential mediating role of ApoCs in these relationships. This prospective study included 3,009 and 2,724 participants with baseline serum retinol and RBP4 data, respectively. Over a 9-year follow-up among 2,621 participants, 1,136, 127, 696, and 662 were categorized into MetS-free, recovered, incident MetS, and persistent MetS groups, respectively. Midway through the study, ApoC1-4 levels were measured in 2316 participants. Adjusted odds ratios (95% CIs) for the highest (vs. lowest) tertile of retinol and RBP4 levels were 3.63 (2.69-4.92) and 5.64 (4.05-7.92) for 9-year persistent MetS, respectively. The corresponding hazard ratios (95% CIs) were 1.67 (1.39-2.01) and 1.67(1.38, 2.03) for incident MetS, and 0.65 (0.41-1.03) and 0.44 (0.28, 0.70) for recovered MetS (all P-trends<.05). A synergistic association of retinol and RBP4 with MetS risk was observed for persistent MetS. Higher levels of retinol or RBP4 were associated with increased concentrations of ApoC1-4, which were linked to a greater risk of incident and persistent MetS. A newly developed composite score (ApoCS), derived from ApoC1-4 levels, explained 30.5% and 24.5% of the association between retinol or RBP4 and MetS, with ApoC2 and ApoC3 contributing predominantly to this connection. Our study identified notable positive correlations between serum retinol and RBP4 levels and MetS progression, explained by increases in circulating ApoC2 and ApoC3 within a Chinese cohort. Show less
no PDF DOI: 10.1016/j.jnutbio.2025.109892
APOC3
Qingcong Zheng, Rongjie Lin, Du Wang +2 more · 2025 · BMC musculoskeletal disorders · BioMed Central · added 2026-04-24
It remains controversial whether lipids affect osteoporosis (OP) or bone mineral density (BMD), and causality has not been established. This study aimed to investigate the genetic associations between Show more
It remains controversial whether lipids affect osteoporosis (OP) or bone mineral density (BMD), and causality has not been established. This study aimed to investigate the genetic associations between lipids, novel non-statin lipid-lowering drug target genes, and OP and BMD. Mendelian randomization (MR) method was used to explore the genetic associations between 179 lipid species and OP, BMD. Drug-target MR analysis was used to explore the causal associations between angiopoietin-like protein 3 (ANGPTL3) and apolipoprotein C3 (APOC3) inhibitors on BMD. The IVW results with Bonferroni correction indicated that triglyceride (TG) (51:3) (OR = 1.0029; 95% CI: 1.0014-1.0045; P = 0.0002) and TG (56:6) (OR = 1.0021; 95% CI: 1.0008-1.0033; P = 0.0011) were associated with an increased risk of OP; TG (51:2) (OR = 0.9543; 95% CI: 0.9148-0.9954; P = 0.0298) was associated with decreased BMD; and ANGPTL3 inhibitor (OR = 1.1342; 95% CI: 1.0393-1.2290; P = 0.0093) and APOC3 inhibitor (OR = 1.0506; 95% CI: 1.0155-1.0857; P = 0.0058) was associated with increased BMD. MR analysis indicated causal associations between genetically predicted TGs and OP and BMD. Drug-target MR analysis showed that ANGPTL3 and APOC3 have the potential to serve as novel non-statin lipid-lowering drug targets to treat or prevent OP. Show less
📄 PDF DOI: 10.1186/s12891-024-08160-z
APOC3
Lei Wu, Zhong Zhuang, Wenqian Jia +7 more · 2025 · Poultry science · Elsevier · added 2026-04-24
Residual feed intake (RFI) has recently gained attention as a key indicator of feed efficiency in poultry. In this study, 800 slow-growing ducks with similar initial body weights were reared in an exp Show more
Residual feed intake (RFI) has recently gained attention as a key indicator of feed efficiency in poultry. In this study, 800 slow-growing ducks with similar initial body weights were reared in an experimental facility until they were culled at 42 d of age. Thirty high RFI (HRFI) and 30 low RFI (LRFI) birds were selected to evaluate their growth performance, carcass characteristics, and muscle development. Transcriptome and weighted gene co-expression correlation network analyses of pectoral muscles were conducted on six LRFI and six HRFI ducks. The results revealed that selecting for LRFI significantly reduced feed consumption (P < 0.05) and improved feed efficiency without affecting the growth performance, slaughter rate, or meat quality of ducks (P > 0.05). Moreover, compared with HRFI ducks, LRFI ducks had a lower pectoral muscle fat content (P < 0.05), larger muscle fiber diameter and area (P < 0.05), and lower muscle fiber density (P < 0.05). There were significant differences in gene expression between LRFI and HRFI ducks, with 102 upregulated and 258 downregulated genes, which were enriched in the PPAR signaling pathway, adipocytokine signaling pathway, actin cytoskeleton regulation, ECM-receptor interaction, and focal adhesion. The expression of genes associated with fat and energy metabolism, including ACSL6, PCK1, APOC3, HMGCS2, PRKAG3, and G6PC1, was downregulated in LRFI ducks, and weighted gene co-expression correlation network analysis identified PRKAG3 as a hub gene. Our findings indicate that reduced mitochondrial energy metabolism may contribute to the RFI of slow-growing ducks, with PRKAG3 playing a pivotal role in this biological process. These findings provide novel insights into the molecular changes underlying RFI variation in slow-growing ducks. Show less
📄 PDF DOI: 10.1016/j.psj.2024.104613
APOC3
Guotong Sun, Yaowen Xu, Xiuwen Liang +2 more · 2025 · International immunopharmacology · Elsevier · added 2026-04-24
The etiology of hyperlipidemia is complex, and our understanding of its underlying mechanisms is limited. Effective therapeutic strategies for hyperlipidemia remain elusive. This study aimed to confir Show more
The etiology of hyperlipidemia is complex, and our understanding of its underlying mechanisms is limited. Effective therapeutic strategies for hyperlipidemia remain elusive. This study aimed to confirm the effect of curcumin on hyperlipidemia treatment and elucidate the precise mechanism. A high-fat diet-induced hyperlipidemia model using C57BL/6J mice and HaCaT cells was established. Co-immunoprecipitation and immunofluorescence were performed to detect protein interactions, and immunoprecipitation coupled with Western blotting was used to assess protein succinylation. 40 μM of curcumin administration promoted cell viability, increased the levels of glutathione peroxidase, glutathione, catalase, and superoxide dismutase, while reducing reactive oxygen species activity and the levels of triglycerides and malondialdehyde. Additionally, curcumin attenuated the development of hyperlipidemia in vivo. Mechanistically, 100 mg/kg of curcumin promoted O-GlcNAcylation and increased the expression of O-linked N-acetylglucosamine transferase in HaCaT cells. Furthermore, apolipoprotein C3 was identified as a substrate of O-linked N-acetylglucosamine transferase, and O-GlcNAcylation of apolipoprotein C3 enhanced its stability. Rescue experiments further verified that curcumin exerts its effects by regulating apolipoprotein C3 expression. In conclusion, these findings provide novel insights into the treatment of hyperlipidemia. Show less
no PDF DOI: 10.1016/j.intimp.2024.113647
APOC3
Yi Li, Zhu Ni, Xiao-Yong Xia +7 more · 2025 · Frontiers in molecular biosciences · Frontiers · added 2026-04-24
Metabolic disorders and neurocognitive diseases frequently co-occur, yet the specific mechanisms driving this comorbidity remain elusive. While epidemiological associations are well-documented, the ca Show more
Metabolic disorders and neurocognitive diseases frequently co-occur, yet the specific mechanisms driving this comorbidity remain elusive. While epidemiological associations are well-documented, the causal links between these conditions are complex and incompletely understood, necessitating a systems-level investigation into their shared biological architecture. This study integrates large-scale human genetics with experimental Network-informed Mendelian randomization identified bidirectional causalities, including a 14% elevated dementia risk from type 2 diabetes and protective effects of obesity against parental Alzheimer's disease (AD). The study identified a signature encompassing key lipid metabolism hubs This multi-modal investigation provides a robust framework that converges on a high-confidence, 13-gene signature of lipid dysregulation as a central mechanistic interface, offering a powerful set of prioritized targets for future functional validation and therapeutic development at the metabolic-neurocognitive nexus. Show less
📄 PDF DOI: 10.3389/fmolb.2025.1712198
APOE
Yanyu Shi, Zepeng Zhang, Jiaqi Liu +7 more · 2025 · Frontiers in immunology · Frontiers · added 2026-04-24
Atherosclerosis (AS) is a chronic inflammatory disorder driven by dysregulated lipid metabolism and remains a leading cause of cardiovascular morbidity. The Shen-Hong-Tong-Luo (SHTL) preparation has d Show more
Atherosclerosis (AS) is a chronic inflammatory disorder driven by dysregulated lipid metabolism and remains a leading cause of cardiovascular morbidity. The Shen-Hong-Tong-Luo (SHTL) preparation has demonstrated clinical benefit in stabilizing atherosclerotic plaques, yet its molecular mechanisms are not fully defined. This research sought to elucidate the protective effects exerted by SHTL on AS progression. To investigate the impact of SHTL on macrophage function and plaque stability, we utilized ApoE SHTL markedly attenuated the progression of AS, demonstrated by reduced plaque formation within both the aortic root and aorta, diminished plasma lipid concentrations, and suppressed inflammatory responses. SHTL demonstrates significant anti-inflammatory and lipid-regulatory effects, attenuating AS progression through the PPARγ/Mfge8 pathway, thereby enhancing macrophage efferocytosis. These findings highlight a novel mechanism by which SHTL may contribute to preventing and treating atherosclerotic diseases. Show less
📄 PDF DOI: 10.3389/fimmu.2025.1727378
APOE
Min Zhao, Jiwei Jiang, Linlin Wang +8 more · 2025 · Frontiers in neuroscience · Frontiers · added 2026-04-24
Although previous studies have reported associations between gonadotropins, testosterone, and Alzheimer's disease (AD), their longitudinal relationships with cognitive decline and temporal lobe atroph Show more
Although previous studies have reported associations between gonadotropins, testosterone, and Alzheimer's disease (AD), their longitudinal relationships with cognitive decline and temporal lobe atrophy remain insufficiently characterized. This study examined the association between baseline hormone levels and cognitive decline and temporal lobe volume loss trajectories, and whether these associations vary by sex or This study included 490 participants (378 MCI/112 AD; 311 men/179 women; mean age = 75.01 ± 7.52) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Baseline plasma levels of gonadotropins (FSH, LH) and total testosterone (TT) were measured using Luminex xMAP multiplex immunoassay. Cognitive decline was assessed longitudinally through MMSE and ADAS-Cog 13 scores. Temporal lobe atrophy was quantified using tensor-based morphometry of 1.5T MRI scans, with bilateral temporal lobe volumes scaled to a normalized reference (1,000 = baseline). Linear mixed effects models were employed to relate baseline plasma hormones to longitudinal cognitive performance and temporal lobe volume. Longitudinal analyses showed that higher baseline FSH levels were associated with faster cognitive decline (MMSE: β = -0.025, The results indicate that in individuals across the AD spectrum, elevated gonadotropin levels may exert deleterious, domain-specific effects on cognitive decline or temporal lobe atrophy. Women with lower TT levels may experience faster cognitive progression. Although future studies incorporating additional longitudinal hormone measurements and cognitive trajectories are warranted, our results underscore the importance of gonadotropins and testosterone in AD progression. Show less
📄 PDF DOI: 10.3389/fnins.2025.1696274
APOE
Xiaofan Wei, Baiwan Zhou, Juanling Li +2 more · 2025 · Frontiers in aging neuroscience · Frontiers · added 2026-04-24
To explore neurodynamic bases underlying subjective cognitive decline (SCD) based on edge-centric functional network. 211 SCD patients and 210 healthy controls (HC) were recruited from the Alzheimer's Show more
To explore neurodynamic bases underlying subjective cognitive decline (SCD) based on edge-centric functional network. 211 SCD patients and 210 healthy controls (HC) were recruited from the Alzheimer's Disease Neuroimaging Initiative. Edge time series (ETS) were obtained based on resting-state functional magnetic resonance data. The top 10% co-fluctuation signals of all time points in ETS were extracted to construct the high-amplitude frame networks, and the co-fluctuation signals from the remaining time points were used to construct the low-amplitude frame networks. In both network states, the graph theory and network-based statistics (NBS) analyses were used to compare SCD and HC. The correlation of the imaging indicators with cognitive scores and apolipoprotein E (APOE) ε4 genes was performed by Spearman correlation analysis. SCD exhibited lower peak amplitude and longer trough-to-trough duration (TTD) compared to HC. In both network states, the normalized clustering coefficient, normalized characteristic path length, small-worldness, and global efficiency of SCD were significantly reduced, and the altered nodal centralities of SCD predominantly exhibited a decreasing trend. However, the high-amplitude frame network identified more altered brain regions compared to the low-amplitude frame network. Furthermore, a SCD-related subnetwork was found in the high-amplitude frame network, which was composed of 11 brain regions and 13 edges. TTD was positively related to the number of APOE ε4 genes; the normalized characteristic path length, the betweenness centrality of right postcentral gyrus, and the connection between bilateral angular gyrus were correlated with cognitive scores. Our findings demonstrate that the edge-centric network framework reveals details of brain network alterations in SCD through different perspectives, and these alterations hold potential as novel biomarkers for SCD. Show less
📄 PDF DOI: 10.3389/fnagi.2025.1596537
APOE
Shaoshen Wang, Xiangxiang Shi, Xiaoqi Li +9 more · 2025 · International journal of nanomedicine · added 2026-04-24
The early, precise, and safe management of vulnerable atherosclerotic plaques (VAPs) remains a formidable clinical challenge. Here, we present a targeted nanotherapeutic approach in which osteopontin- Show more
The early, precise, and safe management of vulnerable atherosclerotic plaques (VAPs) remains a formidable clinical challenge. Here, we present a targeted nanotherapeutic approach in which osteopontin-targeted nanoparticles encapsulate luteolin (NPs-Lut) for the precise delivery and treatment of VAPs. This engineered system enables site-specific accumulation and sustained release of luteolin at plaque sites. We innovatively constructed an osteopontin-targeted drug delivery system designed for vulnerable atherosclerotic plaques, in which luteolin and atorvastatin were successfully encapsulated. The system demonstrated sustained-release capability in vitro, and its biosafety and histocompatibility were comprehensively evaluated both in vitro and in vivo. Moreover, therapeutic efficacy was further assessed in ApoE In vivo evaluation in ApoE This work provides a robust and translationally promising nanoplatform for the precision treatment of VAPs, offering a novel strategy for safe and effective intervention in atherosclerotic cardiovascular disease. Show less
📄 PDF DOI: 10.2147/IJN.S566896
APOE
Chengxi Wu, Yaoyao Li, Yuting Liu +7 more · 2025 · International journal of nanomedicine · added 2026-04-24
In the microenvironment of atherosclerosis (AS), low-density lipoprotein (LDL) accumulates in injured endothelial areas and undergoes oxidation, thereby generating oxidized LDL (ox-LDL). The formation Show more
In the microenvironment of atherosclerosis (AS), low-density lipoprotein (LDL) accumulates in injured endothelial areas and undergoes oxidation, thereby generating oxidized LDL (ox-LDL). The formation of ox-LDL, in turn, not only amplifies endothelial cell (EC) dysfunction but also triggers macrophage polarization into the pro-inflammatory M1 phenotype. This cascade results in increased inflammatory cytokine secretion and exacerbated lipid accumulation. Therefore, a dual-targeting strategy aimed at both ECs and macrophages to inhibit the vicious circle between inflammation and lipids is a promising avenue for AS treatment. Simvastatin (SIM)-loaded nanomicelles (PLA-PEG/SIM) were prepared using the thin-film hydration method. Then, platelet membrane (PM) was coated the nanomicelles via sonication to obtain PM@PLA-PEG/SIM dual-targeting biomimetic nanoparticles. The morphological features of the nanoparticles were assessed by transmission electron microscopy (TEM). Cytotoxicity was evaluated using the CCK-8 assay and live/dead cell staining. Their targeting ability toward ECs and macrophages was assessed by flow cytometry and confocal laser scanning microscopy (CLSM). The biosafety, targeting ability, and therapeutic efficacy of PM@PLA-PEG/SIM against AS were further validated in ApoE PM@PLA-PEG/SIM effectively reduced the drug toxicity of SIM, exhibiting good biocompatibility. In vitro, cell experiment results showed that the nanoparticles inhibited foam cell formation, decreased interleukin-6 (IL-6) expression, and increased interleukin-4 (IL-4) and interleukin-10 (IL-10) expression by promoting macrophage repolarization. In vivo, results indicated that the formulation demonstrated excellent plaque-targeting ability. More importantly, the plaque area and lipid levels in the PM@PLA-PEG/SIM group were lowest, and plaques were most stable, showing its best therapeutic efficiency. PM@PLA-PEG/SIM alleviated progression of AS by co-targeting ECs and macrophages to inhibit the vicious cycle between inflammation and lipids. Our study provides a new strategy for the treatment of the disease by the co-targeting biomimetic nanoparticle. Show less
📄 PDF DOI: 10.2147/IJN.S558039
APOE
Yue Xu, Yuan Zhou, Kun Li +3 more · 2025 · Human genomics · BioMed Central · added 2026-04-24
Phosphorylation is a crucial post-translational modification mechanism that enhances proteomic diversity, and its malfunction has been confirmed to be associated with complex traits, especially brain Show more
Phosphorylation is a crucial post-translational modification mechanism that enhances proteomic diversity, and its malfunction has been confirmed to be associated with complex traits, especially brain disorders. One of the factors contributing to this malfunction is the missense mutations given that they may alter the peptides flanking the phosphorylated residues. However, the specific effects of these missense mutations on phosphorylation remain unclear. To ascertain these, a deep learning phosphorylation prediction model (DeepMEP), which is the first to be developed on a Chinese-brain-specific phosphorylation dataset (CBMAP), was established to bridge the phosphorylation and peptides. The impact of each missense mutation on phosphorylation was subsequently quantified based on the differences between the outputs of reference and mutant protein sequences. A permutation test adjusting for the confounding factors was finally employed to estimate the enrichment for high-impact mutations in disease-associated genomic loci. DeepMEP achieved superior predictive performance compared with other existing tools on both CBMAP and publicly available datasets. Enrichment analysis revealed the high-impact mutations were significantly enriched in GWAS signals for Alzheimer’s disease (AD) and Parkinson’s disease (PD). The corresponding genes of those missense mutations overlapping with GWAS included Our study demonstrated that DeepMEP effectively captured the impact of missense mutations on phosphorylation and highlighted an enrichment of high-impact mutations in AD- and PD-associated genomic loci. The online version contains supplementary material available at 10.1186/s40246-025-00898-4. Show less
📄 PDF DOI: 10.1186/s40246-025-00898-4
APOE
Ni Wang, Yanan Xu, Jiahui Li +7 more · 2025 · Journal of microbiology and biotechnology · added 2026-04-24
As a chronic lipid driven arterial disease, dyslipidemia is one of the most critical risk factors for atherosclerosis (AS). The gut microbiota plays an important role in regulating host lipid metaboli Show more
As a chronic lipid driven arterial disease, dyslipidemia is one of the most critical risk factors for atherosclerosis (AS). The gut microbiota plays an important role in regulating host lipid metabolism disorders. Studies have shown that the herb "Gualou-Xiebai" (GLXB) can effectively regulate the blood lipid levels of ApoE Show less
📄 PDF DOI: 10.4014/jmb.2510.10023
APOE
Jing Xu, Wen-Zhao Wen, Jun-Hui Zhao +3 more · 2025 · Foods (Basel, Switzerland) · MDPI · added 2026-04-24
📄 PDF DOI: 10.3390/foods14244267
APOE
Chan Liu, Juan Liu, Yan-Yang Wang +2 more · 2025 · Molecular neurobiology · Springer · added 2026-04-24
The APOE4 variant was the strongest genetic risk factor for sporadic Alzheimer's disease (AD). Individuals with APOE4 have an increased risk of developing the disease at an early age of onset. Similar Show more
The APOE4 variant was the strongest genetic risk factor for sporadic Alzheimer's disease (AD). Individuals with APOE4 have an increased risk of developing the disease at an early age of onset. Similarly, APOE4 carriers are predisposed to high cholesterol levels and tend to have an increased risk of cardiovascular disease (CVD). The global allele frequency of APOE4 was 13.7%, underlining its widespread impact on global human health. Conversely, the relatively rare APOE2 allele was a genetic protective factor against AD and CVD. However, the mechanisms underlying this association remain to be elucidated. The apolipoprotein E (APOE) protein coats lipoprotein particles and mediates lipid transport and metabolism in the peripheral circulation and central nervous system (CNS). Although initial studies causally linked APOE lipoprotein particles (APOE particles) with lipid homeostasis, our understanding of the physiological and pathological effects of APOE particles has extended to amyloid-β (Aβ) accumulation, tau hyperphosphorylation and spread, as well as neuroinflammation in AD initiation and progression. Moreover, the most examined functions of APOE particles are reverse cholesterol transport, anti-inflammatory, anti-oxidation, and improvement of endothelial dysfunction in atherosclerotic CVD. This review outlines what is known about the structure and functions of APOE particles, emphasizing their involvement in AD and CVD pathogenesis, while also considering the crosstalk between the peripheral circulation and CNS. In addition, we discuss how these APOE particles act as therapeutic targets. Show less
📄 PDF DOI: 10.1007/s12035-025-05629-3
APOE
Tong Zhou, Anqi Chen, Yuanyuan Sun +3 more · 2025 · Molecular neurobiology · Springer · added 2026-04-24
Stroke, including cerebral ischemia and cerebral hemorrhage, is one of the leading causes of mortality worldwide. The narrow therapeutic window limits the efficacy and applicability of current treatme Show more
Stroke, including cerebral ischemia and cerebral hemorrhage, is one of the leading causes of mortality worldwide. The narrow therapeutic window limits the efficacy and applicability of current treatments such as thrombolysis and endovascular thrombectomy. This urgent need for effective therapies has shifted the focus towards mitigating the secondary inflammation and tissue damage that follow intracerebral hemorrhage. Spatial transcriptomic analysis of mouse brains post-ischemia has revealed that the ApoE-TREM2 signaling pathway is central to the complex interactions between microglia and various surrounding cells, coordinating the formation of neuroglial scars, suggesting that TREM2 is a key participant in post-stroke pathology and a potential therapeutic target. This review aims to provide an insightful synthesis of TREM2, including its structure, signaling pathways, and the role of its soluble form, sTREM2, in the nervous system. We systematically summarize the signaling pathways and mechanisms by which TREM2 modulates microglial function, including promoting phagocytosis, exerting anti-inflammatory properties, modulating lipid metabolism, and enhancing cell survival. We also highlight the TREM2's interactions with other cell types post-stroke, such as macrophages and B cells. Furthermore, we discuss advancements in TREM2-targeted drug development, emphasizing the potential of TREM2 agonists and antibodies to modulate microglial function and inflammation, which sets the stage for future research and drug development. Show less
📄 PDF DOI: 10.1007/s12035-025-05622-w
APOE
Fangyuan Zhang, Fei Lu, Mingfei Shi +5 more · 2025 · Journal of inflammation research · added 2026-04-24
Extensive research has demonstrated that gut microbiota and its metabolites-including short-chain fatty acids, trimethylamine N-oxide (TMAO), and bile acids-play a crucial role in the pathophysiology Show more
Extensive research has demonstrated that gut microbiota and its metabolites-including short-chain fatty acids, trimethylamine N-oxide (TMAO), and bile acids-play a crucial role in the pathophysiology of coronary artery disease (CAD).The bidirectional interaction between the gut microbiota and the cardiovascular system significantly influences host metabolic and inflammatory homeostasis. As a result, targeted modulation of the gut microbiota emerges as a promising adjunctive therapeutic strategy for CAD, offering potential benefits with minimal side effects. This study aims to elucidate the therapeutic mechanisms of the clinically validated Chinese medicine formula HJ11 in mitigating coronary heart disease (CHD), with a particular focus on its regulation of the heart-gut axis and associated atherosclerotic processes. This study established an ApoE-/- mouse model of atherosclerosis and treated with HJ11 via gavage.We investigated the effects of HJ11 on the gut microenvironment in these atherosclerotic mice. Gut microbial composition and faecal metabolite profiles were analyzed using 16S rDNA sequencing and metabolomics. Additionally, an in vitro model of atherosclerosis was used to examine whether HJ11 exerts anti-inflammatory effects by modulating the TLR4/MYD88/IκB-α signaling pathway. HJ11 exerted protective effects on coronary atherosclerosis by reducing systemic serum lipid levels and inhibiting plaque formation, vascular inflammation, and collagen deposition, while also alleviating aortic injury. It suppressed endothelial inflammation and inhibited the proliferation of vascular smooth muscle cells. In the gut, HJ11 alleviated intestinal structural damage and enhanced barrier integrity. Notably, it promoted the function of Akkermansia, a beneficial bacterium known to influence TLR4 expression. Finally, in an in vitro atherosclerosis model, HJ11 decoction inhibited cell proliferation and migration by inactivating the TLR4/MYD88/IκB-α signaling pathway-an effect that was abolished by TLR4 overexpression. Show less
📄 PDF DOI: 10.2147/JIR.S523304
APOE
Qiankun Chen, Leying Wang, Yuan Wei +8 more · 2025 · Microbiome · BioMed Central · added 2026-04-24
The ocular surface microbiome (OSM) in patients with meibomian gland dysfunction (MGD) differs from that of healthy individuals. However, the precise role of OSM in MGD remains unknown. Therefore, we Show more
The ocular surface microbiome (OSM) in patients with meibomian gland dysfunction (MGD) differs from that of healthy individuals. However, the precise role of OSM in MGD remains unknown. Therefore, we aimed to investigate the mechanism of OSM in the inflammation of MGD and the effects of topical sodium butyrate (SB) treatment in ApoE ApoE Five-month-old ApoE ApoE Show less
📄 PDF DOI: 10.1186/s40168-025-02294-5
APOE
Xin Lou, Yihua Shi, Yi Qin +13 more · 2025 · Cell death & disease · Nature · added 2026-04-24
Temozolomide (TMZ) is a first-class clinical drug for patients with pancreatic neuroendocrine tumors (pNETs). However, the therapeutic effects of TMZ are limited because of the chemoresistance of pNET Show more
Temozolomide (TMZ) is a first-class clinical drug for patients with pancreatic neuroendocrine tumors (pNETs). However, the therapeutic effects of TMZ are limited because of the chemoresistance of pNET cells, which has not been fully elucidated. Here, we demonstrate that the reprogramming of lipid metabolism regulates TMZ resistance in patients with pNETs. Via integrated multiomics sequencing, apolipoprotein E (APOE), which is a critical lipid carrier, was identified to be highly increased in the tissue and blood plasma of patients in the TMZ treatment group compared with those in the control group. Further mechanistic studies revealed that TMZ treatment promotes the expression and secretion of APOE, which binds to its surface receptor known as scavenger receptor class B member 1 (SCARB1), thus leading to increased uptake of exogenous lipids to remodel cellular lipid metabolism and activation of the homologous recombination repair (HRR) pathway to repair DNA damage via the β-catenin-BRCA1/2 axis. The interruption of APOE-mediated lipid uptake via a SCARB1 inhibitor named as block lipid transport-1 (BLT-1), suppressed TMZ-induced HRR activation and sensitized tumor cells to TMZ treatment in preclinical models, including PDCs, PDOs, and PDXs. In addition, APOE expression levels were shown to be positively correlated with BRCA1/2 expression in clinical specimens and online databases. This study reveals a new functional role of APOE that leads to chemoresistance in patient treatment. Our findings suggest the potential of combined administration of BLT-1 to overcome TMZ chemoresistance and improve treatments for patients with pNETs. Show less
📄 PDF DOI: 10.1038/s41419-025-08317-1
APOE
Zhezhe Chen, Qiongjun Zhu, Hong Xu +8 more · 2025 · Nature communications · Nature · added 2026-04-24
Many patients are suffering from atherosclerosis without typical risk factors, which can cause severe cardiovascular complications. Trimethylamine N-oxide (TMAO), derived from gut microbes, is a key u Show more
Many patients are suffering from atherosclerosis without typical risk factors, which can cause severe cardiovascular complications. Trimethylamine N-oxide (TMAO), derived from gut microbes, is a key unconventional contributor to the development of atherosclerosis. Here we present a strategy performed by orally administered nano-functionalized probiotics (PDMF@LGG) to inhibit TMAO through the gut microbiota-trimethylamine (TMA)-TMAO axis. PDMF@LGG, composed of polydopamine-coated Lacticaseibacillus rhamnosus GG and nanoparticles based on a reactive oxygen species (ROS)-responsive polymeric prodrug of fluoromethylcholine (FMC), can promote the retention of probiotics and nanoparticles in the intestine to persistently scavenge elevated ROS and release drugs. This process suppresses TMA production and absorption, lowering plasma TMAO levels. The therapeutic effects on male ApoE Show less
📄 PDF DOI: 10.1038/s41467-025-66448-7
APOE
Chenming Liu, Sutong Xu, Hongkai Yao +7 more · 2025 · Journal of neuroinflammation · BioMed Central · added 2026-04-24
Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders characterized by β-amyloid (Aβ) deposition, neurofibrillary tangles, neuronal loss, and neuroinflammation. It represen Show more
Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders characterized by β-amyloid (Aβ) deposition, neurofibrillary tangles, neuronal loss, and neuroinflammation. It represents a growing global health crisis. Although astrocytes contribute to neuroinflammatory cascades, their molecular regulators in AD progression remains elusive. Here, through single-cell transcriptomic analysis, we identified SerpinA3N as a disease-progressive modulator upregulated in AD astrocytes, with expression levels correlating with pathological severity. Astrocytic SerpinA3N knockdown in AD mice rescued cognitive deficits across multiple behavioral tests, and concurrently attenuated neuroinflammatory responses, as evidenced by decreased astrocytic/microglial activation and reduced cytotoxic substance release. Moreover, histopathological analyses demonstrated decreased neuronal loss and Aβ deposition following SerpinA3N knockdown. Mechanistically, we elucidated that SerpinA3N cooperated with APOE to exacerbate AD pathology through NFκB signaling activation. Our study uncovers a novel astrocyte-mediated pathogenic cascade driving AD progression and establishes SerpinA3N as a promising therapeutic target for neuroinflammation modulation in AD. Show less
📄 PDF DOI: 10.1186/s12974-025-03644-8
APOE